The intestinal microbiota in chronic liver disease.

[1]  Kazuhide Yamamoto,et al.  Role of gut microbiota in liver diseases , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  R. Weiskirchen,et al.  Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease , 2012, Journal of Inflammation.

[3]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[4]  Casey T. Weaver,et al.  Reciprocal interactions of the intestinal microbiota and immune system , 2012, Nature.

[5]  R. Knight,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[6]  V. Tremaroli,et al.  Functional interactions between the gut microbiota and host metabolism , 2012, Nature.

[7]  H. Anders,et al.  Quantitative Expression of C-Type Lectin Receptors in Humans and Mice , 2012, International journal of molecular sciences.

[8]  A. Viale,et al.  Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice , 2012, The Journal of experimental medicine.

[9]  D. Sinderen,et al.  Gut microbiota composition correlates with diet and health in the elderly , 2012, Nature.

[10]  L. Tang,et al.  Gut-Derived Lipopolysaccharide Promotes T-Cell–Mediated Hepatitis in Mice through Toll-Like Receptor 4 , 2012, Cancer Prevention Research.

[11]  S. Vogel,et al.  The Asp299Gly Polymorphism Alters TLR4 Signaling by Interfering with Recruitment of MyD88 and TRIF , 2012, The Journal of Immunology.

[12]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[13]  H. Mulcahy,et al.  Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  C. Reis e Sousa,et al.  Signaling by myeloid C-type lectin receptors in immunity and homeostasis. , 2012, Annual review of immunology.

[15]  E. Elinav,et al.  Inflammasomes: far beyond inflammation , 2012, Nature Immunology.

[16]  A. Gewirtz,et al.  Toll-like receptor-gut microbiota interactions: perturb at your own risk! , 2012, Annual review of physiology.

[17]  Richard A. Flavell,et al.  Inflammasomes in health and disease , 2012, Nature.

[18]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[19]  M. Odenthal,et al.  Toll‐like receptor 2–mediated innate immune response in human nonparenchymal liver cells toward adeno‐associated viral vectors , 2012, Hepatology.

[20]  G. Szabo,et al.  Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. , 2011, World journal of gastroenterology.

[21]  T. Berg,et al.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[22]  Hong-Yang Wang,et al.  Nuclear factor high‐mobility group box1 mediating the activation of toll‐like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice , 2011, Hepatology.

[23]  F. Bushman,et al.  Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes , 2011, Science.

[24]  S. Yun,et al.  Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea , 2011, Inflammatory bowel diseases.

[25]  H. Dupont,et al.  The intestinal microbiota and chronic disorders of the gut , 2011, Nature Reviews Gastroenterology &Hepatology.

[26]  Baoli Zhu,et al.  Characterization of fecal microbial communities in patients with liver cirrhosis , 2011, Hepatology.

[27]  Jun-wen Yang,et al.  Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet , 2011, BMC complementary and alternative medicine.

[28]  A. Dolganiuc,et al.  Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells , 2011, Hepatology.

[29]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  R. Ophoff,et al.  Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9 , 2011, Hepatology.

[31]  Richard A. Flavell,et al.  NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis , 2011, Cell.

[32]  E. Elinav,et al.  Regulation of the antimicrobial response by NLR proteins. , 2011, Immunity.

[33]  J. Clemente,et al.  Diet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans , 2011, Science.

[34]  D. Brenner,et al.  Innate immunity in alcoholic liver disease. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[35]  Gordon D. Brown,et al.  Syk-coupled C-type lectins in immunity , 2011, Trends in immunology.

[36]  P. Zhu,et al.  Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. , 2011, Human gene therapy.

[37]  T. Joh,et al.  Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis , 2011, Journal of hepato-biliary-pancreatic sciences.

[38]  Ajit Sood,et al.  Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial) , 2011, The American Journal of Gastroenterology.

[39]  A. Dolganiuc,et al.  Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells , 2011, Hepatology.

[40]  A. Dolganiuc,et al.  Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. , 2011, Gastroenterology.

[41]  Michael Fuchs,et al.  Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. , 2011, Gastroenterology.

[42]  J. Tschopp,et al.  Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses , 2010, Proceedings of the National Academy of Sciences.

[43]  H. Jaeschke,et al.  Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury. , 2010, Toxicology and applied pharmacology.

[44]  M. Barone,et al.  Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[45]  S. Massart,et al.  Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa , 2010, Proceedings of the National Academy of Sciences.

[46]  H. El‐Serag,et al.  The changing pattern of epidemiology in hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[47]  M. Imamura,et al.  The TLR4/TRIF-Mediated Activation of NLRP3 Inflammasome Underlies Endotoxin-Induced Liver Injury in Mice , 2010, Gastroenterology research and practice.

[48]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[49]  R. Ley,et al.  Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5 , 2010, Science.

[50]  C. Leevy,et al.  Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.

[51]  J S Bajaj,et al.  Review article: the modern management of hepatic encephalopathy , 2010, Alimentary pharmacology & therapeutics.

[52]  E. Latz.  The inflammasomes: mechanisms of activation and function. , 2010, Current opinion in immunology.

[53]  T. Sauerbruch,et al.  p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ , 2009, Gut.

[54]  Mengji Lu,et al.  Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. , 2009, Journal of hepatology.

[55]  Thomas F. Tedder,et al.  Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism , 2009, Science.

[56]  D. Gotthardt,et al.  Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. , 2009, Journal of hepatology.

[57]  R. Odze,et al.  Pathologic Features of Ulcerative Colitis in Patients With Primary Sclerosing Cholangitis: A Case-control Study , 2009, The American journal of surgical pathology.

[58]  Yan Shi,et al.  Inflammasome-mediated regulation of hepatic stellate cells. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[59]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[60]  F. Sutterwala,et al.  Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. , 2009, The Journal of clinical investigation.

[61]  D. Torres,et al.  Nonalcoholic fatty liver disease. , 2008, Clinics in liver disease.

[62]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[63]  A. Bergquist,et al.  Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[64]  S. Bischoff,et al.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. , 2008, The Journal of nutrition.

[65]  Michael Charlton,et al.  Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? , 2008, Hepatology.

[66]  S. Msika,et al.  High Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Morbid Obesity: A Contributor to Severe Hepatic Steatosis , 2008, Obesity surgery.

[67]  Yosuke Osawa,et al.  TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.

[68]  S. Ahrné,et al.  Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[69]  J. Miquel,et al.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. , 2007, Journal of hepatology.

[70]  B. Carter,et al.  Intestinal Failure-Associated Liver Disease: Management and Treatment Strategies Past, Present, and Future , 2007, Seminars in liver disease.

[71]  Olivia T. Abar,et al.  A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C , 2007, Hepatology.

[72]  Keith G. Tolman,et al.  Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease , 2007 .

[73]  M. Washington.  Autoimmune liver disease: overlap and outliers , 2007, Modern Pathology.

[74]  R. Williams.  Review article: bacterial flora and pathogenesis in hepatic encephalopathy , 2007, Alimentary pharmacology & therapeutics.

[75]  K. Michelsen,et al.  Toll-like receptors and innate immunity in gut homeostasis and pathology , 2007, Current opinion in hematology.

[76]  S. Lewin,et al.  Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein , 2007, Hepatology.

[77]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[78]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[79]  J. Ruland,et al.  Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity , 2006, Nature.

[80]  K. Migita,et al.  Human intrahepatic biliary epithelial cells function in innate immunity by producing IL‐6 and IL‐8 via the TLR4‐NF‐κB and ‐MAPK signaling pathways , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[81]  K. Lindor,et al.  Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. , 2006, Seminars in liver disease.

[82]  P. Dítě,et al.  Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. , 2005, Hepato-gastroenterology.

[83]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[84]  C. Nwokolo,et al.  Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non‐alcoholic steatohepatitis , 2005, Alimentary pharmacology & therapeutics.

[85]  D. Vergani,et al.  Primary biliary cirrhosis is characterized by IgG3 antibodies cross‐reactive with the major mitochondrial autoepitope and its Lactobacillus mimic , 2005, Hepatology.

[86]  Masahiro Ito,et al.  Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. , 2005, Journal of autoimmunity.

[87]  A. Burroughs,et al.  Infection, coagulation, and variceal bleeding in cirrhosis , 2005, Gut.

[88]  S. Riordan,et al.  Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis , 2004, Hepatology.

[89]  R. Coppel,et al.  Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic‐metabolizing bacterium , 2003, Hepatology.

[90]  T. Therneau,et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. , 2003, Gastroenterology.

[91]  E. Björnsson,et al.  Small Intestinal Motility Disturbances and Bacterial Overgrowth in Patients With Liver Cirrhosis and Portal Hypertension , 2003, American Journal of Gastroenterology.

[92]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[93]  J. Ludwig,et al.  Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.

[94]  J. Aponte,et al.  Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis , 2001, American Journal of Gastroenterology.

[95]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[96]  I. Roberts-Thomson,et al.  The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis , 2001, Gut.

[97]  B. Campillo,et al.  Intestinal permeability in liver cirrhosis: relationship with severe septic complications. , 1999, European journal of gastroenterology & hepatology.

[98]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[99]  T. Sauerbruch,et al.  Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins , 1998, Hepatology.

[100]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[101]  A. Basile,et al.  Ammonia and GABA‐ergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy , 1997, Hepatology.

[102]  W. Vogel,et al.  Prognosis in nonalcoholic steatohepatitis. , 1995, Gastroenterology.

[103]  J. Costerton,et al.  Antibacterial activity of bile salts against common biliary pathogens , 1993, Digestive Diseases and Sciences.

[104]  M. Taniai,et al.  Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis , 1993, Journal of gastroenterology and hepatology.

[105]  C. Kallenberg,et al.  Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases , 1993, Hepatology.

[106]  Y. Haviv,et al.  Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[107]  D. Huhn,et al.  RELATION BETWEEN ESCHERICHIA COLI R(ROUGH)-FORMS IN GUT, LIPID A IN LIVER, AND PRIMARY BILIARY CIRRHOSIS , 1989, The Lancet.

[108]  M. Nāẓim,et al.  Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. , 1989, Hepato-gastroenterology.

[109]  P. Corrodi.  Jejunoileal bypass: change in the flora of the small intestine and its clinical impact. , 1984, Reviews of infectious diseases.

[110]  P. Hylemon,et al.  Linkage of gut microbiome with cognition in hepatic encephalopathy. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[111]  D. Vergani,et al.  Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. , 2004, Journal of hepatology.

[112]  E. Quigley,et al.  Hepatobiliary complications of total parenteral nutrition. , 1993, Gastroenterology.

[113]  J. Such,et al.  Spontaneous Bacterial Peritonitis , 1997, Seminars in liver disease.

[114]  D. Tuma,et al.  Effect of antibiotics in the prevention of jejunoileal bypass-induced liver dysfunction. , 1982, Digestion.

[115]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[116]  P. Hedqvist,et al.  ヒトにおけるアレルゲン誘発ぜん息後の15‐ケト‐13,14‐ジヒドロ‐プロスタグランジンF2αの血しょう値上昇 , 1974 .